The Acorda Therapeutics, Inc. (NASDAQ:ACOR) second quarter 2023 financial and business update provided today by the company's CFO, Tierney Saccavino, is providing an update on the company's second quarter 2023 financial and business update.  According to the company's investor alert, on August 8, 2018, the company announced that it would be raising its sales guidance for the second quarter of 2023.  According to the SEC's alert, the company's new guidance for the second quarter of 2023 represents a 12% increase over the first half of the year and represents substantial growth over the first half of the year.  The company also announced that it would be raising its guidance for the second half of the year.  The company's website and brand campaign, which is called "For the Fighters," highlights that the return of symptoms or OFF periods between regular doses of INBRIJA may cause people with Parkinson's to avoid important moments of their lives such as those related to their family or friends, their interest, their exercise.  The company also announced that it has agreed to pay a $2.5 million upfront payment to Acorda Therapeutics, Inc., a subsidiary of Acorda Therapeutics, for a total of $16.9 million.  The settlement is pending approval by the U.S. District Court for the District of Columbia.  The SEC's continuing investigation is being conducted by Michael Gesser and Tierney Saccavino, and the litigation will be led by Tierney Saccavino.  The SEC appreciates the assistance of the U.S. Attorney's Office for the District of Columbia, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.